France Biotech, the French Association of Life Sciences entrepreneurs, is organizing its 4th Investor Day, on June 4th in Boston, ahead of the BIO Convention, the annual international meeting for life
France Biotech, the French Association of Life Sciences entrepreneurs, is organizing its 4th Investor Day, on June 4th in Boston, ahead of the BIO Convention, the annual international meeting for life sciences.
Considering the major global public health challenges, the Healthtech sector, bringing together disruptive innovations in Biotech, Medtech and European Digital Tech, will present a selection of its most promising companies to American investors specialized in healthcare.
For Maryvonne Hiance, Chairman of France Biotech: \’The scientific and technological excellence of French HealthTech, associated with our world-class healthcare system and environment, contributes to making Europe the most attractive region in terms of investments. The sector must quickly lift barriers, including funding, for its further development. That is the reason why this 4th Investor Day in Boston, where a real French life Science hub is located with French researchers and entrepreneurs, is an opportunity to present our potential to healthcare-focused US investment funds.\’
The group of French and European companies, led by France Biotech and its partners – EuropaBio, Business France, Dechert, Euronext, Invest Securities, NewCap, Sofinnova – is composed of public and private companies. They will be available to meet American investors during one-on-one meetings that will be held from 7:00 am to 1:00 pm at the Hyatt Regency Boston.
|Companies having already announced their participation:
Abivax, Amoéba, Carthera, Amoéba, Diabeloop, Erytech, Genkyotex, Inventiva, Lysogène, Nosopharm,Ose Immunotherapeutics,
Osivax, Pathoquest, Pharmaleads, Pixium Vision, Stemcis, Theradiag, Theranexus, Thrombogenics, Wandercraft
All Day (Monday)